XTL BIOPHARMACEUTICALS ANNOUNCES RECEIPT OF ORPHAN-DRUG DESIGNATION IN THE UNITED STATES FOR THE COMPANY’S DRUG TREATMENT FOR MULTIPLE MYELOMA